Gelonghui September 9丨Zhongyuan Xiehe (600645.SH) announced that its wholly-owned subsidiary Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration on September 9 for the use of VUM02 injections for the treatment of systemic sclerosis. VUM02 injection (human umbilical cord source mesenchymal stem cell injection) is a cryopreservation stem cell preparation independently developed by our company. It is a new human umbilical cord derived mesenchymal stem cell (UC-MSC) drug prepared by isolated, amplified, harvested, and frozen in vitro from selected umbilical cord tissue. Clinical indications increase the treatment of systemic sclerosis.
中源协和(600645.SH)：VUM02注射液获得药物临床试验批准通知书
vcanbio cell & gene engineering corp.,ltd. (600645.SH): VUM02 injection receives drug clinical trial approval notice.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.